Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling

Genome Medicine

Volumn 2, Issue 7, 2010, Pages

  Prentice, Ross L ^a   Paczesny, Sophie ^b   Aragaki, Aaron ^a   Amon, Lynn M ^a   Chen, Lin ^a   Pitteri, Sharon J ^a   McIntosh, Martin ^a   Wang, Pei ^a   Buson Busald, Tina ^a   Hsia, Judith ^c   Jackson, Rebecca D ^d   Rossouw, Jacques E ^e   Manson, JoAnn E ^f   Johnson, Karen ^g   Eaton, Charles ^h   Hanash, Samir M ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c ASTRAZENECA   (United Kingdom)

^d OHIO STATE UNIVERSITY   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A2; BETA 2 MICROGLOBULIN; CYCLOPHILIN A; OROSOMUCOID; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 4;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CORONARY RISK; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MASS SPECTROMETRY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; STROKE;

EID: 78651305024     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm169     Document Type: Article

References (49)

1. Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291:1701-1712. 10.1001/jama.291.14.1701, 15082697, Women's Health Initiative Steering Committee.
2. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333. 10.1001/jama.288.3.321, 12117397, Writing Group for the Women's Health Initiative Investigators.
3. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J, . for the WHI Investigators Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006, 113:2425-2434. 10.1161/CIRCULATIONAHA.105.594077, 16702472, for the WHI Investigators.
4. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ, . for the WHI Investigators Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003, 289:2673-2684. 10.1001/jama.289.20.2673, 12771114, for the WHI Investigators.
5. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R, . for the Women's Health Initiative Investigators Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006, 166:357-365. 10.1001/archinte.166.3.357, 16476878, for the Women's Health Initiative Investigators.
6. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, . for the Women's Health Initiative Investigators Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003, 349:523-534. 10.1056/NEJMoa030808, 12904517, for the Women's Health Initiative Investigators.
7. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A, . for the WHI Investigators Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003, 289:3243-3253. 10.1001/jama.289.24.3243, 12824205, for the WHI Investigators.
8. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT, . for the WHI Investigators Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006, 295:1647-1657. 10.1001/jama.295.14.1647, 16609086, for the WHI Investigators.
9. Katayama H, Paczesny S, Prentice R, Aragaki A, Faca VM, Pitteri SJ, Zhang Q, Wang H, Silva M, Kennedy J, Rossouw J, Jackson R, Hsia J, Chlebowski R, Manson JE, Hanash SM. Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med 2009, 1:47. 10.1186/gm47, 2684668, 19402886.
10. Pitteri SJ, Hanash SM, Aragaki A, Amon LM, Chen L, Busald Buson T, Paczesny S, Katayama H, Wang H, Johnson MM, Zhang Q, McIntosh M, Wang P, Kooperberg C, Rossouw JE, Jackson R, Manson JE, Hsia J, Liu S, Martin L, Prentice RL. Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med 2009, 1:121. 10.1186/gm121, 2808737, 20034393.
11. Faca V, Coram M, Phanstiel D, Glukhova V, Zhang Q, Fitzgibbon M, McIntosh M, Hanash S. Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J Proteome Res 2006, 5:2009-2018. 10.1021/pr060102+, 16889424.
12. Faca V, Pitteri SJ, Newcomb L, Glukhova V, Phanstiel D, Krasnoselsky A, Zhang Q, Struthers J, Wang H, Eng J, Fitzgibbon M, McIntosh M, Hanash S. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res 2007, 6:3558-3565. 10.1021/pr070233q, 17696519.
13. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, Hanash SM. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008, 5:e123. 10.1371/journal.pmed.0050123, 2504036, 18547137.
14. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008, 452:571-579. 10.1038/nature06916, 18385731.
15. The Women's Health Initiative Study Group Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998, 19:61-109. 10.1016/S0197-2456(97)00078-0, 9492970, The Women's Health Initiative Study Group.
16. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative observational study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 2003, 13(9 Suppl):S107-121. 10.1016/S1047-2797(03)00047-4, 14575943.
17. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, Johnson KC, Proulx-Burns L, Pastore L, Criqui M, Daugherty S, . WHI Morbidity and Mortality Committee Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 2003, 13(9 Suppl):S122-128. 10.1016/S1047-2797(03)00048-6, 14575944, WHI Morbidity and Mortality Committee.
18. Rauch A, Bellew M, Eng J, Fitzgibbon M, Holzman T, Hussey P, Igra M, Maclean B, Lin CW, Detter A, Fang R, Faca V, Gafken P, Zhang H, Whiteaker J, States D, Hanash S, Paulovich A, McIntosh MW. Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res 2006, 5:112-121. 10.1021/pr0503533, 16396501.
19. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002, 74:5383-5392. 10.1021/ac025747h, 12403597.
20. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003, 75:4646-4658. 10.1021/ac0341261, 14632076.
21. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3. Article3.
22. Smyth GK. Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor 2005, 397-420. New York: Springer, Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B (Methodological) 1995, 57:289-300.
24. Kanehisa M. The KEGG database. Novartis Found Symp 2002, 247:91-101. discussion 101-103, 119-128, 244-252, full_text, 12539951.
25. The KEGG PATHWAY Database. , http://www.genome.jp/kegg/pathway.html
26. Gorevic PD, Casey TT, Stone WJ, DiRaimondo CR, Prelli FC, Frangione B. Beta-2 microglobulin is an amyloidogenic protein in man. J Clin Invest 1985, 76:2425-2429. 10.1172/JCI112257, 424400, 3908488.
27. Polat H, Yeksan M, Dalmaz M, Kaptanoglu B, Koşar A, Akkuş I. Serum amyloid A protein levels in haemodialysis patients. Nephrol Dial Transplant 1996, 11:1492-1493.
28. Saijo Y, Utsugi M, Yoshioka E, Horikawa N, Sato T, Gong Y, Kishi R. Relationship of B2-Microglobulin to arterial stiffness in Japanese subjects. Hypertens Res 2005, 28:505-511. 10.1291/hypres.28.505, 16231756.
29. Wilson AM, Kimura E, Harada RK, Nair N, Narasimhan B, Meng X-Y, Zhang F, Beck KR, Olin JW, Fung ET, Cooke JP. B2-Microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 2007, 116:1396-1403. 10.1161/CIRCULATIONAHA.106.683722, 17724262.
30. Shinkai S, Chaves PHM, Fujiwara Y, Watanabe S, Shibata H, Yoshida H, Suzuki T. B2-Microglobulin for risk stratification of total mortality in the elderly population. Comparison with Cystatin C and C-reactive protein. Arch Intern Med 2008, 168:200-206. 10.1001/archinternmed.2007.64, 18227369.
31. Stoppini M, Mangione P, Monti M, Giorgetti S, Marchese L, Arcidiaco P, Verga L, Segagni S, Pucci P, Merlini G, Bellotti V. Proteomics of beta2-microglobulin amyloid fibrils. Biochim Biophys Acta 2005, 1753:23-33.
32. Johnsen SP, Hundborg HH, Sørensen HT, Orskov H, Tjønneland A, Overvad K, Jørgensen JO. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab 2005, 90:5937-5941. 10.1210/jc.2004-2088, 16131586.
33. Denti L, Annoni V, Cattadori E, Salvagnini MA, Visioli S, Merli MF, Corradi F, Ceresini G, Valenti G, Hoffman AR, Ceda GP. Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am J Med 2004, 117:312-317. 10.1016/j.amjmed.2004.02.049, 15336580.
34. Bondanelli M, Ambrosio MR, Onofri A, Bergonzoni A, Lavezzi S, Zatelli MC, Valle D, Basaglia N, degli Uberti EC. Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. J Clin Endocrinol Metab 2006, 91:3928-3934. 10.1210/jc.2006-1040, 16882751.
35. Kooijman R, Sarre S, Michotte Y, De Keyser J. Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke?. Stroke 2009, 40:e83-e88. 10.1161/STROKEAHA.108.528356, 19197073.
36. Fournier T, Medjoubi-N N, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000, 1482:157-171.
37. Giardina EG, Raby K, Freilich D, Vita J, Brem R, Louie M. Time course of alpha-1-acid glycoprotein and its relation to myocardial enzymes after acute myocardial infarction. Am J Cardiol 1985, 56:262-265. 10.1016/0002-9149(85)90846-X, 4025163.
38. Mori T, Sasaki J, Kawaguchi H, Handa K, Takada Y, Matsunaga A, Kono S, Arakawa K. Serum glycoproteins and severity of coronary atherosclerosis. Am Heart J 1995, 129:234-238. 10.1016/0002-8703(95)90003-9, 7832094.
39. Held C, Hjemdahl P, Håkan Wallén N, Björkander I, Forslund L, Wiman B, Rehnqvist N. Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm. Atherosclerosis 2000, 148:179-188. 10.1016/S0021-9150(99)00240-3, 10580184.
40. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996, 144:537-547.
41. Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, Stroes ES, Otvos JD, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation 2007, 116:2029-2035. 10.1161/CIRCULATIONAHA.107.704031, 17923573.
42. Matsuda M, Miyahara T, Murai A, Fujimoto N, Kameyama M. Lipoprotein abnormalities in survivors of cerebral infarction with a special reference to apolipoproteins and triglyceride-rich lipoproteins. Atherosclerosis 1987, 68:131-136. 10.1016/0021-9150(87)90103-1, 3689476.
43. Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 2006, 259:259-266. 10.1111/j.1365-2796.2005.01610.x, 16476103.
44. Satoh K, Nigro P, Matoba T, O'Dell MR, Cui Z, Shi X, Mohan A, Yan C, Abe J, Illig KA, Berk BC. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med 2009, 15:649-656. 10.1038/nm.1958, 2704983, 19430489.
45. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf) 2008, 69:347-358. 10.1111/j.1365-2265.2008.03292.x, 18462260.
46. Sandhu MS. Insulin-like growth factor-I and risk of type 2 diabetes and coronary heart disease: molecular epidemiology. Endocr Dev 2005, 9:44-54. full_text, 15879687.
47. Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT. The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 2001, 170:63-70. 10.1677/joe.0.1700063, 11431138.
48. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000, 25:25-29. 10.1038/75556, 10802651.
49. The Women's Health Initiative. , http://www.whi.org